Test | Sensitivity (%) | Specificity (%) | ROC AUC |
---|
HCC versus LC | | | |
4-ion UPLC-MS model | 78.1 | 63.6 | 0.819b,c
|
AFP20 ng/mL
| 37.5 | 93.3 | 0.779d
|
AFP200 ng/mL
| 18.8 | 100.0 | 0.779d
|
4-ion UPLC-MS model | 75.0 | 83.3 | 0.856 |
+ AFP20 ng/mL
a
|
HCC versus CHB | | | |
4-ion UPLC-MS model | 93.8 | 80.0 | 0.864e,f
|
2-ion UPLC-MS model | 96.9 | 80.0 | 0.933g
|
RT 3.40_773.5478 n
| 100.0 | 100.0 | 1.000 |
RT 1.87_534.3902 m/z
| 100.0 | 100.0 | 1.000 |
RT 6.25_369.3538 m/z
| 100.0 | 100.0 | 1.000 |
RT 3.45_822.5670 m/z
| 100.0 | 100.0 | 1.000 |
RT 3.59_770.5691 m/z
| 100.0 | 100.0 | 1.000 |
RT 4.23_851.6090 m/z
| 100.0 | 100.0 | 1.000 |
RT 3.99_826.5920 m/z
| 100.0 | 100.0 | 1.000 |
HCC versus HS | | | |
4-ion UPLC-MS model | 90.6 | 88.2 | 0.946 |
-
ROC receiver operating characteristic, AUC area under the curve, HCC hepatocellular carcinoma, LC liver cirrhosis, AFP alpha-fetoprotein, UPLC ultra performance liquid chromatography, MS mass spectrometry, CHB chronic hepatitis B, RT retention time, n neutral, m/z mass to charge ratio, HS healthy subjects. aCombination of the 4-ion UPLC-MS model and AFP20 ng/mL.
bCompared with AFP20 ng/mL or AFP200 ng/mL, P = 0.616. cCompared with 4-ion UPLC-MS model + AFP20 ng/mL, P = 0.610. dCompared with 4-ion UPLC-MS model + AFP20 ng/mL, P = 0.312. eCompared with 2-ion UPLC-MS model, P = 0.241. fCompared with individual ions, P = 0.047. gCompared with individual ions, P = 0.005